PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Thumbnail
Name:
PIIS2405630818300491.pdf
Size:
1.052Mb
Format:
PDF
Description:
Full text, Open Access article
Download
Authors
Dillon, M
Boylan, Z
Smith, D
Guevara, J
Mohammed, K
Peckitt, C
Saunders, Mark P
Banerji, U
Clack, G
Smith, S
Spicer, J
Forster, M
Harrington, K
Affiliation
The Institute of Cancer Research, London, UKThe Royal Marsden NHS Foundation Trust, London, UK
Issue Date
2018-08

Metadata
Show full item record
Abstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Citation
PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. 2018, 12: 16-20 Clin Transl Radiat Oncol
Journal
Clinical and Translational Radiation Oncology
URI
http://hdl.handle.net/10541/621205
DOI
10.1016/j.ctro.2018.06.001
PubMed ID
30073210
Type
Article
Language
en
ISSN
2405-6308
Collections